Policies and Guidelines
- All application material must be submitted online by Wednesday, July 15, 2021 at 11:59 pm (CT). You
will be prompted to fill out a financial disclosure form when you first
log in (unless a disclosure form was completed in the original call for
abstracts). All presenting authors must provide a financial disclosure
to be accepted for presentation.
- The late-breaking abstract deadline is not intended to be merely
an extension of the general submission deadline. The research must be
new and of sufficient scientific importance to merit special
consideration after the standard abstract deadline.
- Abstract should not be a previously submitted (rejected) abstract, unless there is new information/results.
- Only completed, original research abstracts and case studies will be considered.
- Research abstracts must fit into the research categories:
- General Rehabilitation
- Musculoskeletal and Sports Medicine
- Neurological Rehabilitation
- Pain and Spine Medicine
- Pediatrics Rehabilitation
- Practice Management, Leadership, and Quality Improvement—PM&R residency QI projects will be eligible for submission as an abstract.
- All accepted abstracts will be presented in electronic format via display screens onsite, mobile app, and virtually. In addition, audio recording of the research is required.
- Presenters of accepted abstracts are expected to register and
pay appropriate registration fees for at least the day of the
presentation. No reimbursement or honoraria will be given for paper or
- All authors must be added prior to submission. A maximum of 8 authors can be included per abstract. Co-authors and/or presenting authors cannot be added post acceptance.
- Abstracts are to be no more than 300 words (not including title or author block).
- All research abstracts must include the following:
- Setting (Do not list formal institutional name)
- Interventions (If your study does not contain any interventions, then insert: “Interventions: not applicable.”)
- Main Outcome Measures
- Level of Evidence
- When preparing an abstract, authors are requested to abide by the following general guidelines:
- Authors must not submit abstracts that constitute promotion of a product or service (see policy regarding Commercialism below).
- Authors may not use tables, graphs, or figures in the abstract submission process.
- Authors may not list references in the abstract.
- Authors must report the level of evidence of research studies.
- For research abstract submissions: Submitters will need to select a level of evidence from Level I-V.
- For Program Descriptions (clinical/educational/other): Submitters will select Level V.
- Authors must spell, in full, on first introduction of all acronyms or abbreviations used.
- All numbers should be presented in Arabic numeral form, including numbers from 1 to 10.
- If you refer to brand name drugs, the generic name must be provided.
- We request that non-fluent English speakers have their abstracts edited prior to submission by a proficient English speaker.
The Evidence Committee will evaluate
each abstract based on the components of the structured abstract.
- Acceptance/Rejection notification will be sent via e-mail in mid-September 2021.
- The Review Committee reserves the right to assign presentation
times to suit program needs. If posters are not assigned to a
presentation time, they will still be displayed within AAPM&R’s Research Hub in the PM&R Pavilion throughout
the duration of Annual Assembly and within the Virtual Platform online.
Registrants will be able to peruse the e-posters at their leisure by
using the self-directed digital e-poster kiosks.
- An accepted abstract should be withdrawn from the Annual Assembly presentation and publication if it has been accepted for presentation and/or publication prior to Annual Assembly.
- Accepted abstracts will be minimally edited for style and format
and published in conjunction with PM&R, the Academy’s scientific
journal. The abstract will be available in electronic format in
conjunction with PM&R.
The top ranked research submitted may be selected for inclusion in the “Research Spotlight Podium Presentation” didactic session being held at the 2021 Annual Assembly.
Podium Presentation: A 7-minute oral presentation
of the methodology, results, and conclusions of completed studies. Completed
experimental studies or well-controlled epidemiologic studies may be
presented in this forum.
Commercialism and Disclosure Statements
- Presentations that constitute promotion or advertising will be
rejected. Pervasive or inappropriate use of commercial/trade names is
not allowed. Generic names create a sense of impartiality that are the
accepted standard of practice in submitting scientific abstracts and are
strongly encouraged. No advertising matter of any description may be
distributed, nor may any material be displayed that directly promotes
the commercial interest of any particular company, enterprise, or the
- Presenters must disclose any relevant financial interest in
relationship with or support from manufacturers of any commercial
product(s). AAPM&R will determine if there is a conflict of interest
and will take all appropriate steps to resolve.
- Presenters must disclose the US Food and Drug Administration
(FDA) clearance status of medical devices and pharmaceuticals for the
uses discussed or described in the presentation. "Off label" uses of a
device or pharmaceutical may be described in the presentation as long as
the lack of FDA clearance for this is also disclosed.
- Statements made in presentations are the sole responsibility of
the author(s). Statements should not be viewed as, or representative of,
any formal stance or position taken on any product, subject, or issue
by the Academy or Wiley.
- To be considered for any AMA PRA Category 1 Credit™-designated
activities at the 2021 Annual Assembly (i.e., Research Spotlight Podium or
Poster Presentations), presenting authors must be medical professionals,
MD or MD-equivalent, who are not employed by a pharmaceutical or device
Example of a Structured Abstract
TITLE: New Wheelie Aid for Wheelchairs: Controlled Trial of Safety and Efficacy
PRIMARY AUTHORS: Jane Doe
INSTITUTIONS: Amazing Academic Medical Center
PRESENTATION TYPE: Original Research Abstract
CURRENT CATEGORY: General Rehabilitation
Objective (Abstracts Only): To test hypotheses that people learning to
perform aided wheelies (AW) with a new self-deploying wheelie aid (WA)
are safer than those using the conventional wheelie (CW), are more
successful at learning the skills, learn more quickly, and find such
skills less difficult.
Case Diagnosis (Case Reports Only):
Design (Abstracts Only): Randomized, controlled study.
Setting (Required for Abstracts and Case Reports): Wheelchair obstacle course
Participants (Abstracts Only): 42 subjects randomly assigned to the CW (n=23) or AW (n=19) groups.
Case Description (Case Reports Only):
Interventions (Abstracts Only): We performed static tests on a WA
-modified wheelchair occupied by a test dummy, and attempted to teach
each subject to perform a set of 14 wheelie-related skills.
Discussion (Case Reports Only):
Main Outcome Measures (Abstracts Only): Visual analog scale (VAS) of
safety, percentage of subjects able to learn the skills, the time
required, and subjective difficulty scores (from 1 for "very easy" to 5
for "very difficult").
Results (Abstracts) or Assessment/Results (Case Reports): Up to 11° of anti-tip device stability was available without the
WA extending beyond the rearmost aspect of the rear wheel in the resting
position. For the CW and AW groups, the mean ± standard deviation VAS
safety scores were 43%±27% and 98%±2%.
Conclusions (Required for Abstracts and Case Reports): The WA provides
stability and wheelie-like function without interfering with
maneuverability. Although both groups were equally successful, learning
to perform AW is safer, fast, and less difficult than learning CWs.
Level of Evidence - Abstract Submission Role: Level II
Financial Disclosures: None
Reprinted with permission.
Questions regarding abstract submissions? Email email@example.com.